About theriva biologics - TOVX
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
TOVX At a Glance
Theriva Biologics, Inc.
9605 Medical Center Drive
Rockville, Maryland 20850
| Phone | 1-301-417-4364 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -23,739,000.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TOVX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.488 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.528 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.334 |
TOVX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,483,687.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TOVX Liquidity
| Current Ratio | 1.744 |
| Quick Ratio | 1.744 |
| Cash Ratio | 1.304 |
TOVX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -56.913 |
| Return on Equity | -137.817 |
| Return on Total Capital | -131.795 |
| Return on Invested Capital | -126.818 |
TOVX Capital Structure
| Total Debt to Total Equity | 17.09 |
| Total Debt to Total Capital | 14.596 |
| Total Debt to Total Assets | 6.018 |
| Long-Term Debt to Equity | 13.151 |
| Long-Term Debt to Total Capital | 11.231 |